Coronary Artery Disease Pipeline: Trailblazing Advancements with Over 30 Leading Companies Developing Revolutionary Therapies | DelveInsight

The Coronary Artery Disease market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as GHelixmith, Amgen, Angionetics, Xylocor Therapeutics, and Regio Biosciences. These industry pioneers are transforming treatment strategies and redefining the future of Coronary Artery Disease, bringing new hope to patients worldwide.

DelveInsight's "Coronary Artery Disease Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Coronary Artery Disease market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Coronary Artery Disease drugs, the Coronary Artery Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Coronary Artery Disease Pipeline Report
• DelveInsight's Coronary Artery Disease Pipeline analysis depicts a robust space with 30+ active players working to develop 25+ pipeline drugs for Coronary Artery Disease treatment.
• The leading Coronary Artery Disease companies include Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, Regio Biosciences, and others are evaluating their lead assets to improve the Coronary Artery Disease treatment landscape.
• Key Coronary Artery Disease pipeline therapies in various stages of development include Selatogrel, XTR 003, AdVEGFXC1, Revacept, XTR004, MCRcI stem cells, PET MPI, Inclisiran, AZD-5718, VM202, Evolocumab, Ad5-FGF4, REG-101, and others.
• In March 2025, Caristo Diagnostics announced it received FDA 510(k) clearance for its CaRi-PlaqueTM technology, an AI-assisted image analysis application designed to aid in the diagnosis of coronary artery disease (CAD).
• In March 2025, the FDA approved the first generics of Xarelto (rivaroxaban) 2.5 mg tablets, an anticoagulant to prevent deep vein thrombosis in adults with peripheral artery disease and to reduce the risk of major cardiovascular events in adults with coronary artery disease.
• In November 2024, HeartLung Technologies, a Houston-based AI company, announced that it has received 510(k) clearance from the U.S. FDA for its new software, AutoChamber. This software assesses chest CT scans for indicators of coronary artery disease (CAD) and other serious heart conditions, focusing on opportunistic heart evaluations.
• In September 2024, SpectraWAVE, Inc., a medical imaging company dedicated to enhancing treatment and outcomes for patients with coronary artery disease (CAD), announced that it raised $50 million in a Series B funding round.
• In September 2024, GE HealthCare (Nasdaq: GEHC) announced FDA approval of FlyrcadoTM (flurpiridaz F 18), the first positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD)

Request a sample and discover the recent breakthroughs happening in the Coronary Artery Disease pipeline landscape @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Coronary Artery Disease Overview
Coronary artery disease (CAD), also known as coronary heart disease, is a common heart condition in which the coronary arteries, which supply blood to the heart, become narrowed or blocked. This reduced blood flow limits the delivery of oxygen and nutrients to the heart muscle. Cholesterol buildup (plaques) and inflammation are typically the main causes of CAD.

Symptoms of coronary artery disease arise when the heart is not receiving enough oxygen-rich blood. Individuals with CAD may experience chest pain (angina) and shortness of breath due to decreased blood flow. A complete blockage of the arteries can lead to a heart attack. CAD often develops gradually over several decades, and its symptoms may remain unnoticed until a significant blockage or a heart attack occurs.

Find out more about Coronary Artery Disease medication @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr.

Coronary Artery Disease Treatment Analysis: Drug Profile
Flurpiridaz F-18: GE Healthcare
Flurpiridaz F-18 is a fluorine-18-labeled imaging agent developed by Lantheus Medical Imaging for the diagnosis of coronary artery disease (CAD), the leading cause of heart disease. This investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent is being evaluated in clinical trials. GE Healthcare has initiated a second Phase III clinical trial to assess the use of Flurpiridaz F-18 Injection in PET MPI for detecting CAD. The agent is currently in Phase III clinical trials for the treatment of coronary artery disease.

Evolocumab: Amgen
Evolocumab injection is used to reduce the risk of stroke, heart attack, or the need for coronary artery bypass graft (CABG) surgery in individuals with cardiovascular disease. It is also used, either alone or in combination with other cholesterol-lowering treatments such as statins or ezetimibe (Zetia), to lower low-density lipoprotein (LDL) cholesterol levels, also known as "bad cholesterol." In patients with familial heterozygous hypercholesterolemia or homozygous familial hypercholesterolemia, Evolocumab helps reduce LDL cholesterol through its action as a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor monoclonal antibody. By blocking the production of LDL cholesterol, it helps prevent cholesterol buildup in the arteries, improving blood flow to vital organs like the heart and brain. Evolocumab is currently in Phase III clinical trials for the treatment of coronary artery disease.

Key Coronary Artery Disease Therapies and Companies
• Flurpiridaz F-18: GE Healthcare
• Evolocumab: Amgen
• Revacept: advanceCor
• Atuliflapon: AstraZeneca
• Selatogrel: Idorsia Pharmaceuticals
• AdVEGFXC1: XyloCor Therapeutics

Learn more about the novel and emerging Coronary Artery Disease pipeline therapies @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Coronary Artery Disease Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Coronary Artery Disease Pipeline Report
• Coverage: Global
• Key Coronary Artery Disease Companies: Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, Regio Biosciences, and others.
• Key Coronary Artery Disease Pipeline Therapies: Selatogrel, XTR 003, AdVEGFXC1, Revacept, XTR004, MCRcI stem cells, PET MPI, Inclisiran, AZD-5718, VM202, Evolocumab, Ad5-FGF4, REG-101, and others.

Dive deep into rich insights for drugs used for Coronary Artery Disease treatment; visit @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Coronary Artery Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Coronary Artery Disease Pipeline Therapeutics
6. Coronary Artery Disease Pipeline: Late-Stage Products (Phase III)
7. Coronary Artery Disease Pipeline: Late-Stage Products (Phase III)
8. Coronary Artery Disease Pipeline: Mid-Stage Products (Phase II)
9. Coronary Artery Disease Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.